1. Scrip
  2. >>Business

‘New GSK’ Still Has Some Convincing To Do

Vaccine And Speciality Medicines The Focus

 
• By Andrew McConaghie

Once the consumer health division is spun out in mid-2022, a leaner ‘new GSK’ must set about delivering on its promising pipeline – and proving its skeptics wrong.

GSK syringes
The 'New GSK' aims to deliver growth from its vaccines and speciality medicines pipeline, plus a steady but flat income from established general medicines. • Source: Alamy

GlaxoSmithKline has unveiled its strategy for growth over the next 10 years, arguing it can achieve a compound annual growth rate of more than 5% in revenues and 10% in profits, based on a new wave of innovative products.

Key to that strategy is the spin-out of the company’s consumer health division, set to take place in mid-2022, which will leave behind a ‘new GSK’ focused on vaccines and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 
• By Alaric DeArment

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.

ASCO: Lupin Presents Early Data On PRMT5 Inhibitor

 
• By Vibha Ravi

ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.

MetaVia Sees Obesity Opportunities Despite Challenging US Market

 
• By Jung Won Shin

Despite new challenges related to obesity drug insurance coverage in the US, MetaVia's CEO is confident in the company's novel contender, which unlike rival GLP-1 therapies doesn’t require dose titration.